Cara Therapeutics (NASDAQ: CARA) reported Q4 EPS of ($0.59), $0.14 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $3 million versus the consensus estimate of $9.42 million.
Guidance:
Cara expects that the current unrestricted cash and cash equivalents and available-for-sale marketable securities will be sufficient to fund our currently anticipated operating plan into 2026. Current operating plan reflects the impact of our prioritization announcement in January 2024 which includes costs related to our pivotal program in NP.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.